Jason A. Mouabbi, MD Efforts leveraging targets implicated in CDK 4/6 resistance for patients with hormone receptor (HR)–positive, HER2-negative breast cancer have resulted in the development of several up-and-coming classes of endocrine therapies along with the optimization of targeted therapies, according to Jason A. Mouabbi, MD.
“There have been a lot of advances recently, and what I call a ‘big bang’ of novel endocrine therapies are going to come to the market [soon],” Mouabbi said in an interview with OncLive ® regarding a State of the Science SummitTM on breast cancer, which he chaired. In the interview, Mouabbi highlighted ongoing research to integrate newer endocrine therapies into the armamentarium for first-line HR-positive breast cancer, such as selective estrogen receptor degraders (SERDs) including elacestrant (Orserdu) and camizestrant. Elacestrant gained FDA approval in 2023 based on positive data from the phase 3 EMERALD trial (NCT03778931).
1 Camizestrant is currently being evaluated in the phase 1 SERENA-1 trial (NCT03616587) and in additional SERENA trials in combination therapy approaches, after demonstrating superior progression-free survival outcomes vs fulvestrant (Faslodex) in the phase 2 SERENA-2 trial (NCT04214288). 2 Mouabbi also discussed early data with other emerging drug classes, including complete estrogen receptor antagonists (CERANs), proteolysis-targeting chimeras (PROTACs), and selective CDK4 inhibitors. One such PROTAC, vepdegest.